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Abstract
Introduction: Equine superficial digital flexor tendon injury is a well-accepted model of human tendon injury and
is routinely treated with local injections of autologous mesenchymal stem cells (MSCs). Identification of a clinically
safe medium for short-term cryopreservation of MSCs prior to cell implantation would streamline laboratory and
clinical procedures for autologous regenerative therapies. Veterinary experience with short-term (MSCs prepared
after the injury has occurred) cryopreserved MSCs in naturally occurring injury in the horse will be of value to
human practitioners.
Methods: Equine bone marrow derived MSCs were cryopreserved in 6 different solutions consisting of 20 % serum,
10 % DMSO and 70 % media or 95 % serum and 5 % DMSO. Serum was autologous serum, commercially available
pooled equine serum or fetal bovine serum (FBS). Cell survival, morphology and growth kinetics were assessed by
total cell number, measurement of growth kinetics, colony-forming-unit-assay and morphology of MSCs after
monolayer culture post-thaw.
Results: There were no significant differences in post-thaw viability, total cell number, morphology scores or
growth kinetics among the 6 solutions. Post thaw viabilities from each group ranged from 80-90 %. In all solutions,
there were significantly fewer MSCs and the majority (99 %) of MSCs remained in the original generation 24 hours
post-thaw. Seventy two hours post-thaw, the majority of MSCs (50 %) were proliferating in the fourth generation.
Mean colony count in the CFU-F assay ranged from 72 to 115 colonies.
Conclusions: Each of the serum sources could be used for short-term cryopreservation of equine bone marrow
derived MSCs. Prior to clinical use, clinicians may prefer autologous serum and a lower concentration of DMSO.
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Introduction
The equine athlete is a well-accepted model for stem cell
therapies in musculoskeletal injury [1]. This is because
the horse suffers from naturally occurring superficial
digital flexor tendon injury that is similar to humans,
and culture-derived and expanded mesenchymal stem
cells (MSCs) are being used to treat these injuries [2].
Use of clinical practices in equine cellular therapies that
are acceptable in human medicine would be beneficial to
help ascertain the value of stem cell therapy for tendon
injury in this naturally occurring large animal model.
The ideal stem cell preparation, whether frozen or fresh,
is an ongoing debate in medicine [3–6]. Cryopreserved
MSCs are used in approximately 35 % of published MSC
clinical trials [7]. However, in veterinary medicine the
majority of laboratories preparing MSCs for horses
throughout the world do so with fresh cells [8]. This is not
to state that MSCs have not been previously frozen, but
that immediately prior to implantation in the patient the
MSCs are in monolayer culture and are prepared for injec-
tion immediately prior to clinical use with transport to the
animal site in cooled media. Identification of a cryopreser-
vation medium that allows for immediate clinical use of
MSCs post thaw would be beneficial to streamline labora-
tory and clinical procedures and reduce associated costs.
It is also possible that the cryopreservation process itself
induces cell selection of “stronger” MSCs or induces
greater MSC activity and expansion potential, which could
translate to improved stem cell efficacy [9].
Because of the potential benefits of using cryopreserved
MSCs, and the use of cryopreserved MSCs in human clin-
ical trials, cryopreserved MSCs should be investigated in
the treatment of naturally occurring tendon injury in
horses. The first step in using cryopreserved MSCs in
equine veterinary patients is to identify the ideal medium
for cryopreservation. To do this, the effect on short-term
viability and growth of MSCs post thaw must be
understood [10]. Our objective was to determine whether
a clinically acceptable formulation and serum source for
short-term cryopreservation of equine bone marrow-
derived MSCs would preserve normal viability, morph-
ology, and normal growth kinetics post thaw. Six different
freezing solutions were tested with differing serum supple-
mentation sources and concentrations of dimethyl sulfox-
ide (DMSO). Different DMSO formulations were tested to
determine whether a low concentration of DMSO was suf-
ficient to preserve viability and growth of MSCs frozen in
a slow-freezing method. Different serum sources were
tested to determine whether an autologous serum source
was sufficient to preserve viability and growth. We hy-
pothesized that there would be no differences in the post-
thaw viability, morphology, and cell growth kinetics in
MSCs cryopreserved in autologous, allogeneic, or xeno-
geneic media or with different concentrations of DMSO.
Methods
Bone marrow-derived MSC isolation, expansion, and
cryopreservation
All animal procedures were approved by the institution’s
animal care and use committee (IACUC 2012–079). No
horses were euthanized for this study. Bone marrow-
derived MSCs were isolated from nine healthy horses
ranging in age from 5 to 16 as described previously [11].
Briefly, bone marrow was collected from mildly sedated
horses into heparinized syringes for a final concentration
of 5000 units of heparin per 30 ml marrow. Red blood cell
lysis was performed with ammonium chloride (7.7 mg/ml
NH4Cl; 2.06 mg/ml hydroxymethane-aminomethane;
pH 7.2) [11]. The remaining nucleated cellular portion of
the marrow was plated at 175 μl original raw marrow
volume/cm2 (Corning, Corning, NY, USA) and main-
tained at 37 °C, 5 % CO2 in humidified air. Culture
medium (Dulbecco’s modified Eagle’s medium 1 g/l glu-
cose (Mediatech, Manassas, VA, USA) supplemented with
10 % fetal bovine serum (FBS) (HyClone Inc., Logan, UT,
USA), 2.5 % HEPES buffer (Corning), and 10,000 units/ml
penicillin, 10,000 μg/ml streptomycin, 25 μg/ml ampho-
tericin B (Life Technologies, Grand Island, NY, USA)) was
exchanged three times per week. Once colonies or mono-
layers reached 70 % of confluence, cultures were passaged
until there was a minimum number of MSCs available for
the experiment of 3 × 106 MSCs and for other experi-
ments not outlined in this manuscript. During each pas-
sage, cells were detached from culture flasks by incubation
with 5 ml per 175 cm2 of 0.25 % trypsin–ethylenediamine
tetraacetic acid (EDTA) (Corning) for 5 minutes followed
by collection, serum neutralization of trypsin with 5 ml
per 175 cm2 of 10 % equine serum in Hank’s balanced salt
solution (HBSS), and centrifugation. MSCs were resus-
pended in culture medium and reseeded into new tissue
culture flasks at 5000 MSCs/cm2. Once the minimum
total MSC number was achieved, MSCs were collected,
rinsed by centrifugation three times, and a portion frozen
in each cryopreservation solution at 10 × 106 MSCs/ml.
Freezing media were a formulation of 20 % serum, 10 %
DMSO, and 70 % minimum essential media (MEM)
(20/10/70) or a formulation of 95 % serum and 5 %
DMSO (95/5). Serum sources were FBS, commercially
available pooled equine serum (Thermo Scientific,
Waltham, MA, USA), or autologous serum (FBS, allo-
genic, autologous). The same lot was used throughout the
project for both FBS and pooled equine serum. After drop-
wise addition to the freezing solution, the cell suspension
was transferred to cryovials (Thermo Scientific) which were
placed immediately in a room-temperature isopropyl alco-
hol freeze container (Thermo Scientific), and stored in a
−80 °C freezer for 24 hours. After 24 hours, the vials were
transferred to liquid nitrogen storage in the liquid phase
[12].
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Immunophenotyping
MSCs grown for each horse underwent immunopheno-
typing for expression of MHCII (Bio-Rad, Raleigh, NC,
USA), CD44 (Bio-Rad), CD29 (Beckman Coulter, Brea,
CA, USA), CD90 (VMRD Inc., Pullman, WA, USA), and
CD45RB (VMRD Inc.) using flow cytometry. Antibodies
were chosen based on previously published work and dilu-
tion of 1:400 for CD90, 1:10 for CD45RB, and 1:100 for
CD44, CD29, and MHCII [13, 14]. MSCs were aliquoted
at 1 million cells per Eppendorf tubes in 50 μl staining
buffer.
MSCs stained with primary antibodies (MHCII, CD29,
and CD44) had antibody dilution added and were incu-
bated for 45 minutes at 4 °C. Pellets were centrifuged
(400 × g, 7 brake) for 5 minutes. Pellets were washed with
200 μl Dulbecco’s phosphate-buffered saline (DPBS; Lonza,
Walkersville, MD, USA) and centrifuged again before being
resuspended in DPBS for analysis.
MSCs stained with secondary antibodies (CD90,
CD45RB) had antibody dilution added and cells were
incubated on ice for 15 minutes before being centrifuged
(400 g, 4 °C) for 3 minutes. Cells were washed with
100 μl DPBS and centrifuged twice. One hundred microli-
ters of secondary antibody dilution (1:100) was added and
cells were incubated on ice in the dark for 15 minutes be-
fore being centrifuged (400 × g) for 5 minutes. Cells were
washed with 200 μl DPBS and centrifuged again before
being resuspended in 500 μl DPBS for analysis. Both
primary and secondary antibodies had 5 μl 7-AAD
(Biolegend, San Diego, CA, USA) added immediately
prior to analysis for assessment of viability.
Trilineage differentiation
Multipotency of MSCs used in the experiment was
assessed by inducing trilineage differentiation on MSCs
from eight of nine horses using techniques described previ-
ously [15–17]. For chondrogenic differentiation, three
aliquots of 500,000 MSCs were centrifuged (300 × g,
5 minutes, 4 °C, 7 brake) in polypropylene conical
tubes to form pellets. Supernatant was aspirated gen-
tly not to disturb the pellet and 1 ml chondrogenic
media was added. Chondrogenic media containing
Dulbecco’s modified Eagle’s medium 4.5 g/l glucose
supplemented with 1 % FBS, 2.5 % hepes buffer, 10,000
units/ml penicillin, 10,000 μg/ml streptomycin, 25 μg/ml
amphotericin B, 0.2 % transforming growth factor beta
(Life Technologies, Grand Island, NY, USA), 301.89 μg
dexamethasone (Sigma Aldrich, St. Louis, MO, USA),
50 μg/ml L-ascorbic acid (Sigma Aldrich), 40 μg/ml pro-
line (Sigma Aldrich), and 1 % ITS premix (VWR, Radnor,
PA, USA) were exchanged three times per week for
21 days. Pellets were fixed in 4 % PFA (Sigma Aldrich) for
10 minutes followed by routine embedding, sectioning,
and staining with toluidine blue (Sigma Aldrich).
For adipogenic differentiation, MSCs were seeded to
10 cm plates at 1000 MSCs/cm2. Once the plates reached
70 % confluence, media were exchanged for adipogenic
induction media for 3 days (Dulbecco’s modified Eagle’s
medium F12 (VWR) supplemented with 3 % FBS, 10,000
units/ml penicillin, 10,000 μg/ml streptomycin, 25 μg/ml
amphotericin B, 5 % rabbit serum (Life Technologies),
33 μM/l biotin (Sigma Aldrich), 17 μM/l pantothenate
(Sigma Aldrich), 1 μM/l insulin (Sigma Aldrich), 1 μM/l
dexamethasone, 225 μl isobutylmethylxanthine (Sigma
Aldrich), 89 μl rosiglitazone (Sigma Aldrich)). Media were
then exchanged for adipogenic maintenance media for an
additional 3 days (adipogenic induction media without
isobutylmethylxanthine and rosiglitazone). Induced and
control plates were stained with Oil Red O (Sigma
Aldrich).
For osteogenic differentiation, MSCs were seeded to
10 cm plates at 1000 MSCs/cm2. After reaching 70 % con-
fluence, media were exchanged for osteogenic induction
medium and maintained for 14 and 21 days (Dulbecco’s
modified Eagle’s medium F12 supplemented with 10 %
FBS, 10,000 units/ml penicillin, 10,000 μg/ml streptomycin,
25 μg/ml amphotericin B, 10 μM/l β-glycerophosphate
(Sigma Aldrich), 20 nM/l dexamethasone, and 50 μg/ml
L-ascorbic acid). Plates were stained with 2 % Alizarin
Red (Sigma Aldrich).
Thawing
After storage in liquid nitrogen for 2–5 days, vials were
thawed with gentle agitation at 35 °C in a water bath
until an ice ball was no longer present. Immediately post
thaw, an equal volume of DPBS was added to the cell
suspension. Five minutes later, the cell suspension was
collected and added dropwise to 20 ml DPBS (Lonza).
This thawing method was defined in a pilot project to
this experiment where we determined the importance of
avoiding osmotic shock in the 95/5 formulations
(Additional file 1). A 100 μl aliquot of thawed cell suspen-
sion in DPBS was used for a total cell count and viability
using fluorescein diacetate (67.57 mg/ml) and propidium
iodide (1.35 mg/ml) in DPBS. Counting cell suspensions
were plated on a Nebauer hemocytometer and visualized
by fluorescence microscopy (Olympus, Center Valley, PA,
USA). The live (green) and dead (red) cells were counted.
A total of 10 squares were counted per sample. The cell
suspension was carefully mixed by pipetting and then cen-
trifuged to pellet the cells for removal of freezing solutions
(300 × g, 5 minutes, 4 °C, 7 brake).
Post-thaw cell staining with CellTrace™ label
Cell Trace™ violet dye was used to determine the speed
of cellular proliferation. CellTrace™ violet dye binds to
intracellular amines without interfering with cellular
activity. As the cell divides, the dye is distributed equally
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between the two daughter cells, resulting in dye dilution
that reflects the number of cell divisions which have
occurred since labeling [18, 19] with CellTrace™ (Life
Technologies, ThermoFisher Scientific, Grand Island,
NY 14072). The amount of dye dilution in each cell and
thus the number of cell divisions which have occurred,
or the generation of that cell, is determined using flow
cytometry. A cell that has dye dilution reflecting two cel-
lular divisions is a second-generation cell, and so on.
Post centrifugation, the supernatant was removed and
pelleted MSCs were resuspended in 1 ml DPBS to be la-
beled with CellTrace™ violet dye, as per the manufac-
turer’s instructions. Briefly, cells were labeled in
suspension by adding 1 μl staining solution to 1 ml
DPBS containing ≤10 × 106 cells. CellTrace™ violet dye
and MSCs were incubated for 20 minutes at room
temperature in the dark with gentle agitation every 3 mi-
nutes. Complete media were added at five times the
staining volume and incubated at room temperature in
the dark for an additional 5 minutes. The suspension
was centrifuged, resuspended in complete media at the
same volume, and incubated for another 10 minutes at
room temperature in the dark, with agitation every 3 mi-
nutes. Stained MSCs were then treated as described in
the following for post-thaw monolayer culture of MSCs.
Life Technologies, ThermoFisher Scientific, Grand Is-
land, NY 14072.
Post-thaw monolayer culture of MSCs
Following labeling, MSCs from each condition were
seeded at 10,000 viable MSCs/cm2 to tissue culture flasks
(Corning) to evaluate growth kinetics, viability, and
morphology and 1,000 viable MSCs were seeded to a
10 cm plate for colony-forming unit assay. Cultures were
maintained as already outlined prior to cryopreservation.
Monolayer cultures of MSCs were visualized by micros-
copy and photographed (Olympus) using commercially
available software (cellSens; Olympus). Each monolayer
culture was given a morphology score of excellent (cells
were spindle shaped), good (cells were wider or more star
shaped), fair (cells were flattened and/or contained large
vacuoles), or poor (cells were flattened, vacuolar, and foamy
in appearance) and a debris score of none (<5 floating cells
per 40× field), mild (<20 floating cells per 40× field floating
cells), moderate (<40 floating cells per 40× field), or severe
(≥40 floating cells per 40× field) by an investigator blinded
to treatment group assignment (Table 1). One week after
seeding the 10 cm plates, colonies were stained with 3 %
crystal violet (Sigma Aldrich) and colonies were manually
counted without magnification. The evaluator was masked
to treatment group assignment.
Cell generation assay
After 24 and 72 hours of monolayer culture post thaw,
cells were detached and collected by addition of trypsin–
EDTA. The total cell number was determined. Cells were
colabeled with propidium iodide and flow cytometry was
used to assess the concentration of remaining CellTrace™
cytoplasmic dye. Approximately 12,000–35,000 events
were collected per condition. The cell generation with the
greatest concentration of cytoplasmic dye at 24 hours post
thaw was defined as the parent generation. The ModFit
LT software program (Verity Software House, Topsham,
ME, USA) was used to determine division rates of the
MSCs. Results were reported as the current cell gener-
ation and the proportion of cells in that generation.
Statistical analysis
Raw data were imported to a commercial statistical soft-
ware program (Statistix 9; Analytical Software, Tallahassee,
FL, USA). Differences between the conditions for continu-
ous data were evaluated by one-way analysis of variance
(ANOVA) with Tukey’s post-hoc tests and by Kruskal–
Wallis ANOVA with pairwise comparisons as appropriate
for the data structure. Differences in paired data within a
group were evaluated by the Wilcoxon signed-rank test.
Differences were considered significant when p ≤0.05.
Results
No differences were found in the post-thaw viability,
morphology, and growth kinetics of previously frozen
MSCs with each of the tested solutions. Bone marrow
was collected from nine mixed-breed mares aged 5–16
years. The passage number of MSCs ranged from
passage 3 to passage 6 (Table 2). Differences in passage
number were due to the need for different total numbers
of MSCs from each horse for other experiments not
outlined in this manuscript.
All assay time points were met for each donor and
formulation except for Horse 6 in 95/5FBS, due to a la-
boratory error immediately after CellTrace™ labeling. This
freezing medium (95/5FBS) was repeated later and all
Table 1 Age of mesenchymal stem cell donors and passage number
Morphology Debris
Excellent/none Cells were spindle shaped <5 floating cells per 40× field
Good/mild Cells were wider or more star shaped <20 floating cells per 40× field
Fair/moderate Cells were flattened and/or contained large vacuoles <40 floating cells per 40× field
Poor/severe Cells were flattened, vacuolar, and foamy in appearance ≥40 floating cells per 40× field
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assays were performed. For repetition of Horse 6 95/5FBS,
the same passage was available but had been cryopre-
served for 18 months. Statistical significance was un-
changed with the repeated data for Horse 6 in 95/5 FBS.
Within each solution, there were significantly fewer
viable and attached MSCs at 24 hours post thaw compared
with the number of viable MSCs seeded to each flask
(Fig. 1; 20/10/70FBS, p = 0.02; 20/10/70Allo, p = 0.05; 20/
10/70Auto, p = 0.012; 95/5FBS, p = 0.05; 95/5Allo, p = 0.05;
95/5Auto, p = 0.02).
Between the solutions there were no significant differ-
ences in any of our assays. Immediate post-thaw cell viabil-
ity for each condition ranged from 81 to 88 % (Fig. 2). Cell
debris scores at 24 hours were generally mild to moderate
debris, with one or two horses in each medium having se-
vere debris and one or two horses in each medium with no
debris (Fig. 3). MSCs receiving severe debris scores were
from the same two individual donors. Horse 1 MSCs re-
ceived a debris score of severe for all six freezing solutions
and the total viable MSCs at 24 hours were extremely low,
ranging from 25,000 to 55,000 viable MSCs. MSCs from
one other individual donor (Horse 6) received severe debris
scores in two formulations, 20/10/70FBS and 95/5Auto,
and scores of mild and moderate for all other formulations.
The cell counts at 24 hours were also very low for these
formulations (145,000 and 45,000 MSCs). In contrast to
scores at 24 hours, cell debris scores at 72 hours were gen-
erally none to mild (Fig. 3). Exceptions to this were the
MSCs from the same two individual horses that had
received severe debris scores at 24 hours. The MSCs from
these horses also received worse scores at 72 hours: Horse
1 had moderate debris in all formulations except 20/10/
70FBS and 20/10/70Auto, and Horse 6 had severe debris
in 95/5Auto. Cell morphology scores at both 24 and
72 hours post thaw were generally good to excellent with-
out differences between groups (Figs 3 and 4). Total viable
cell counts were not different between the groups at 24 or
72 hours (Fig. 1). The percentage of confluence at 72 hours
ranged from 70 to 80 % for all conditions. Numbers of
colonies from the 10 cm plates ranged from 72 to 115
colonies (Fig. 5). At 24 hours post thaw, the majority
(mean; standard deviation) of MSCs remained in their par-
ent generation: 20/10/70FBS (98.4 %; 3.15), 20/10/70Allo
(98.2 %; 2.36), 20/10/70Auto (99.5 %; 0.44), 95/5FBS
(98.8 %; 1.48), 95/5Allo (98.6 %; 1.92), and 95/5Auto (98 %;
2.96) (Fig. 6 and Additional file 2). At 72 hours post thaw,
the majority (mean; standard deviation) of MSCs were in
the fourth generation: 20/10/70FBS (54.9 %; 10.25), 20/10/
70Allo (55.1 %; 7.94), 20/10/70Auto (57 %; 10.32), 95/5FBS
(51.5 %; 15.17), 95/5Allo (54.2 %; 12.98), and 95/5Auto
(59.1 %; 11.78) (Fig. 6 and Additional file 3). When the
number of MSCs contributing to the total cell number at
Table 2 Morphology and debris scoring system
Horse Age Passage
1 8 4
2 5 6
3 16 4
4 12 4
5 11 3
6 7 4
7 13 6
8 12 3
9 14 6
Fig. 1 Total viable cell number. Viability of MSCs from nine horses cryopreserved in six different freezing solutions after a 24 hours and b 72 hours in
monolayer culture post thaw (median, quartiles). There were no differences between the groups (24 hours, p= 0.96; 72 hours, p = 0.51). a Dotted line
represents the total number of viable MSCs seeded post thaw. The total viable MSCs at 24 hours post thaw were significantly lower than the cell number
seeded in all groups (20/10/70FBS, p= 0.02; 20/10/70Allo, p= 0.05; 20/10/70Auto, p= 0.01; 95/5FBS, p= 0.05; 95/5Allo, p= 0.05; 95/5Auto, p= 0.02). Allo
allogenic, Auto autologous, FBS fetal bovine serum, 20/10/70 20 % serum, 10 % dimethyl sulfoxide, 70 % minimum essential media, 95/5 95 % serum, 5 %
dimethyl sulfoxide
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72 hours was calculated, based upon the mean proportion
of cells in each generation at 72 hours, it was lower than
the cell count at 24 hours (20/10/70FBS, 65,372; 20/10/
70Allo, 95,865; 20/10/70Auto, 60,675; 95/5FBS, 80,897; 95/
5Allo, 80,033; 95/5Auto, 64,578).
The majority of horses were negative for MHCII,
CD44, and CD45RB and were positive for CD29 and
CD90. Eight of nine horses underwent trilineage differ-
entiation and were positive for osteogenic, chondrogenic,
and adipogenic differentiation (Table 3; Fig. 7).
Discussion
We sought to identify whether a clinically acceptable
medium for short-term cryopreservation of equine bone
marrow-derived MSCs would preserve normal post-thaw
viability and growth. MSCs from nine middle-aged adult
horses at a broad range of passage numbers were utilized
to best mimic the clinical scenario of autologous MSC
therapy where differing total numbers of MSCs might be
required due to differences in tendon lesion size and
severity. Varying concentrations of autologous serum,
pooled equine serum, or FBS; two concentrations of
DMSO; and the presence or absence of a cell culture
media were tested. Standard immediate and longer-term
post-thaw viability assessments included total live and
dead analysis, colony forming units-fibroblast (CFU-F)
assay, and assessment of MSC morphology and cellular
debris. A more novel analysis we used to assess growth
was to stain MSC cytoplasm in a way that would not
interfere with cellular activity and could be accurately
measured by flow cytometry, giving us the number and
frequency of cellular divisions for single cells [20].
Analysis of remaining cytoplasmic dye 24 and 72 hours
after staining allowed evaluation of growth kinetics of
MSCs from each cryopreservation medium, and in com-
bination with total cell numbers and culture scoring en-
abled indirect assessment of post-thaw apoptosis
induction.
One of the benefits of studying stem cell therapies in
the horse is that the horse population, like that of man,
is not homogeneous in genotype or phenotype, unlike
most laboratory species. In addition to genotype and
phenotype differences, individual variation in MSC char-
acteristics, especially in species with diversity, has been
reported [14, 21]. It is important to assess MSCs in
models that more accurately reflect the inherent variabil-
ity among human MSC preparations. Utilizing a greater
number of individuals in MSC experiments better re-
flects responses from a diverse population. Using MSCs
from nine individual donors, we found no differences
between any of the freezing medium formulations in the
post-thaw viability or early growth and morphology of
MSCs by any of our assay methods. However, when we
looked at individual horses, there were marked differ-
ences in cell expansion between the media solutions
72 hours post thaw in a few of the horses. For example,
37 % of MSCs from Horse 4 frozen in 20/10/70Allo were
in generation 5, while the other five freezing solutions
were much lower, ranging from 12 to 31 % of the MSC
population in generation 5. As a contrasting example,
only 0.5 % of MSCs from Horse 6 frozen in 20/10/
70Allo had reached generation 5, while the other five
freezing media had much higher percentages of MSCs in
generation 5, ranging from 6 to 62 %. Had we included
Fig. 2 Percentage of viable cells post thaw. Viability immediately post thaw of MSCs from nine horses cryopreserved in six different solutions
(mean; standard deviation). There were no significant differences between the groups. p = 0.844. Allo allogenic, Auto autologous, FBS fetal bovine
serum, 20/10/70 20 % serum, 10 % dimethyl sulfoxide, 70 % minimum essential media, 95/5 95 % serum, 5 % dimethyl sulfoxide
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one of these horses in a smaller group size, we might
have erroneously identified differences between the
formulations.
The media formulations we tested were either 20 %
serum, 10 % DMSO, and 70 % cell culture media or
95 % serum and 5 % DMSO. The 20/10/70 formulation
was elected as the standard cryopreservation medium
formulation used in cell culture for many cell types.
Within this group, our question was whether use of
xenogen-free serum sources were possible. The 95/5 for-
mulation that has been reported recently was elected to
answer two questions [22]: can an almost entirely au-
tologous product (95 %) and a reduced DMSO concen-
tration be used? The lack of deleterious effects when an
autologous product was used with a low concentration
of DMSO could move cryopreserved MSCs closer to an
off-the-shelf product and would also streamline prepar-
ation of autologous MSCs.
Culture and cryopreservation of MSCs in FBS has
been a standard technique for many years. Because of a
desire to move toward an entirely xenogen-free product
in stem cell therapies, two equine serum sources were
tested. Based upon other work in our laboratory (data
not shown) and that of others [7, 23], we think there are
individual differences in the quality of serum for the
growth of MSCs. Because of these potential variations in
serum quality between individual horses, autologous
serum and a commercially available pooled equine
serum were tested. If individual serum quality differ-
ences exist, they do not appear to negatively affect the
post-thaw viability and growth of MSCs frozen in au-
tologous serum at either concentration we report here.
Therefore, either the commercially available equine
serum or autologous serum can be used for short-term
xenogen-free MSC cryopreservation. An entirely autolo-
gous product versus an allogeneic, xenogen-free product
Fig. 3 Debris and morphology scores. Frequency of a, b debris and c, d morphology scores of MSCs from nine horses cryopreserved in six
different solutions in monolayer culture at a, c 24 and b, d 72 hours post thaw. Allo allogenic, Auto autologous, FBS fetal bovine serum, 20/10/70
20 % serum, 10 % dimethyl sulfoxide, 70 % minimum essential media, 95/5 95 % serum, 5 % dimethyl sulfoxide
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would be desirable to minimize many more risks, both
known and unknown.
Despite being cytotoxic and potentially toxic to the pa-
tient who will receive the cells, 10 % DMSO is the most
commonly used cryoprotectant agent with or without
cell washing for DMSO removal prior to cell infusion to
patients [6, 24, 25]. Because of its cytotoxicity and
varying reports of the effectiveness of lower DMSO con-
centrations in human cell cryopreservation, 5 % DMSO
was also tested [26, 27]. A lower DMSO concentration,
if effective, might minimize toxic effects that occur prior
to freezing and in the immediate post-thaw period when
MSCs are in the cryopreservation medium. Based upon
our results, 5 % DMSO is sufficient as a cryoprotectant
for short-term MSC cryopreservation. Using this lower
concentration of DMSO would be especially important if
a post-thaw rinse of MSCs was delayed or avoided
altogether prior to clinical application.
Lack of differences among the cryopreservation media
we tested is in stark contrast to results of a pilot project
in our laboratory. In the pilot project, the same six freez-
ing solutions and serum sources on MSCs from six
middle-aged horses were tested, but we utilized a very
minor variation in the thawing process. The difference
in the thawing method was that post-thaw MSCs were
slowly transferred in a dropwise manner to a large
volume (20 ml) of DPBS, as has been reported previ-
ously, rather than the stepwise introduction to DPBS
over 5 minutes we report here [8]. This minor difference
in methods resulted in profound deleterious effects of
Fig. 4 Images of monolayer culture. Microscopy images of MSCs from Horse 3 cryopreserved in six different freezing solutions after a 24 hours
and b 72 hours in monolayer culture post thaw. Original magnification 40×, scale bar = 500 μm. Allo allogenic, Auto autologous, FBS fetal bovine
serum, 20/10/70 20 % serum, 10 % dimethyl sulfoxide, 70 % minimum essential media, 95/5 95 % serum, 5 % dimethyl sulfoxide
Fig. 5 Total colony number. Numbers of colonies on CFU-F assay from MSCs cryopreserved in six different freezing solutions (median, quartiles).
One thousand total viable MSCs were seeded to 10 cm plates. Colonies were stained and manually counted without magnification 1 week later.
There were no differences between the groups. p = 0.76. Allo allogenic, Auto autologous, FBS fetal bovine serum, 20/10/70 20 % serum, 10 %
dimethyl sulfoxide, 70 % minimum essential media, 95/5 95 % serum, 5 % dimethyl sulfoxide
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cryopreservation media consisting of 95 % serum of both
equine types with post-thaw viabilities of less than 60 %
(Additional file 1). Susceptibility of all cell types to post-
thaw osmotic shock is well known [28] and enhanced
susceptibility has been suggested in human MSCs [9].
Both an absence of balanced isotonic solution and/or a
lower concentration of cryoprotectant in our 95/5 for-
mulation could have led to increased susceptibility to os-
motic shock. Regardless, it appeared in our pilot project
that the use of 95 % FBS was somewhat protective of the
enhanced susceptibility to osmotic shock in the 95/5 for-
mulation compared with either equine serum source. In
the experiment of this report, careful handling of MSCs
to reduce osmotic shock resulted in no differences
among the 95/5 or 20/10/70 formulations. The import-
ance of MSC handling immediately after the thawing
process should be underscored.
First reported in 2011, post-thaw growth arrest of MSCs
followed by a very rapid proliferation rate of surviving
MSCs was seen in our study [9]. As originally suggested,
this might be selection of “better” MSCs with a younger
phenotype and faster proliferation rate while inducing
apoptosis of the “less strong” MSCs post thaw. Our study
demonstrated a lack of MSC division of the plastic adher-
ent population in the first 24 hours with >95 % of viable
MSCs still in the defined parent generation, and a greater
number of nonadherent cells in the first 24 hours post
thaw reflected by the higher debris scores at 24 hours and
lower total cell count of adherent MSCs after 24 hours of
culture than the number of MSCs seeded for all groups.
These floating cells were likely apoptotic MSCs, rather
than surviving but dysfunctional cells, because much
higher numbers and monolayer densities would have
occurred at 72 hours had the floating cells recovered func-
tion after 24 hours. Additionally, the CFU-F assay colony
number was lower when debris scores at 24 hours were
high (Fig. 8). This growth arrest seemed to recover be-
tween 24 and 72 hours, with the majority of viable MSCs
in the fourth generation, 48 hours later. However, we think
there was incomplete recovery with continued apoptosis in
a portion of MSCs because the total viable cell number at
72 hours was significantly lower than one would expect
given our cellular generation data. An assay of apoptosis
would have been helpful to prove that apoptosis occurred.
Finally, although direct comparisons with growth of MSCs
from the same donors that had not been frozen were not
made, our impression is that the growth during the
72 hours post thaw was much greater than we see during
routine monolayer expansion of fresh MSCs. This is in
contrast to a recent report where post-thaw MSC growth
was not different to suspension stored MSCs where there
was a steady proliferation rate for 4 days [8].
Table 3 Cell surface marker profiles (percent positive)
Horse MHCII CD44 CD29 CD45 CD90
1 1.39 68.7 100 7.27 100
2 1.41 3.19 100 1.56 99.8
3 1.52 1.88 99.8 2.5 83
4 1.13 71.8 100 5.52 89.7
5 1.24 10.8 99.4 14.9 94.7
6 1.83 9.64 100 6.42 99.5
7 60.9 18.7 100 39.5 92.8
8 5.01 48.7 99.9 21.2 90.7
9 45.4 17 99.8 17.7 99.4
Fig. 6 Cell generations post thaw. Percentage of MSCs cryopreserved in six different solutions in generations 1–5 at a 24 hours and b 72 hours post
thaw and monolayer culture (mean). There were no differences between the groups (generation 2, p= 0.82; generation 3, p = 0.84; generation 4, p= 0.82;
generation 5, p = 0.44), Allo allogenic, Auto autologous, FBS fetal bovine serum, 20/10/70 20 % serum, 10 % dimethyl sulfoxide, 70 % minimum essential
media, 95/5 95 % serum, 5 % dimethyl sulfoxide
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A limitation of our study was that cell surface markers,
commonly used to characterize the phenotype of MSCs,
and trilineage differentiation potential in vitro were not
assayed post thawing. These analyses were not per-
formed for two main reasons. First, others have reported
a lack of changes in cell surface markers in fresh versus
post-thaw human and porcine bone marrow-derived
MSCs and that cryopreservation does not change differ-
entiation ability [9, 29-32]. Second, others have reported
lack of changes in cell surface marker profile due to
serum type (autologous serum versus FBS) [33]. There-
fore, we thought the minimal exposure to different
media during freezing and thawing was unlikely to alter
the cell surface marker expression or in vitro differenti-
ation potential, so long as viability and growth were
unchanged.
Another step that is important to note in our design is
that DMSO was removed from MSCs post thaw with a
post-thaw wash by centrifugation. In the clinical setting,
if one used any of our tested conditions immediately
post thaw, a post-thaw wash and centrifugation step
would be required if removal of DMSO was desired.
This washing step would require laboratory involvement
in the clinical procedure, somewhat limiting the off-the-
shelf availability to the treating clinician.
Conclusion
We evaluated the short-term cryopreservation of equine
bone marrow-derived MSCs in solutions consisting of
differing concentrations and types of serum and differing
concentrations of DMSO. A low-tech, commercially
available freezing system that would be affordable in veter-
inary services was used. In this system, equine MSCs did
not have differences in post-thaw viability and growth,
regardless of the cryopreservation formulation or serum
source used. The importance of minimizing osmotic shock
of MSCs immediately post thaw and the potential
increased risk of osmotic shock with different media for
Fig. 8 Debris score versus CFU-F. Total number of colony-forming units plotted against debris scores from MSCs cryopreserved in six different
solutions and maintained in monolayer for 24 hours post thaw. When there was increased debris, there were fewer colonies 1 week later, confirming
that debris consisted of MSCs which did not recover and adhere to plastic at a later time
Fig. 7 Trilineage differentiation. Images of MSCs from Horse 6 after a adipogenic, b chondrogenic, and c osteogenic differentiation. Trilineage
differentiation was confirmed on MSCs from eight of the nine horses prior to cryopreservation. One horse did not have MSCs available to be
tested. Original magnification 200×, scale bar = 100 μm
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cryopreservation as found in our pilot project should be
noted. Additionally, immediately post thaw there was an
apparent lag phase of MSCs with little cellular division
and assumed apoptosis in the first 24 hours post thaw,
followed by rapid MSC growth over the next 48 hours. If a
xenogen-free product with lower concentration of cryo-
protectant is clinically desirable to streamline clinical and
laboratory procedures by use of cryopreserved MSCs, the
use of 95 % autologous serum and 5 % DMSO for the
short-term cryopreservation of equine bone marrow-
derived MSCs is recommended.
Additional files
Additional file 1: Is a figure showing the percentage of viable cells
post thaw. Percentage of viable cells post thaw of MSCs from nine
horses cryopreserved in six different solutions from our pilot project
(median, quartiles). In the pilot project, there was a minor variation in the
thawing process. The viable MSCs were significantly lower when MSCs
were frozen in 95/5Allo and 95/5Auto solutions. (JPEG 442 kb)
Additional file 2: Is a figure showing flow histograms of CellTrace™
dye in MSCs cryopreserved in six different freezing solutions,
24 hours post thaw and monolayer expansion. (JPEG 285 kb)
Additional file 3: Is a figure showing flow histograms of CellTrace™
dye in MSCs cryopreserved in six different freezing solutions,
72 hours post thaw and monolayer expansion. (JPEG 1580 kb)
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